WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. “We are delighted to welcome Keli to the Apellis Board of Directors,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. “Keli has a proven track record of successfully bringin ...

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:45 a.m. PT. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, ...

Legal Investigation - Bragar Eagel & Squire, P C is investigating potential claims against Apellis Pharmaceuticals Inc on behalf of long-term stockholders following a class action complaint filed on August 2 2023 with a Class Period from January 28 2021 to July 28 2023 [2] - The investigation concerns whether the board of directors of Apellis breached their fiduciary duties to the company [2] Allegations - The Complaint alleges that Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Apellis Pharmaceuticals' business and operations during the Class Period [3] - Specifically, Defendants allegedly misrepresented and/or failed to disclose that the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections [3] - As a result, the commercial adoption of SYFOVRE was subject to significant unknown risk factors [3] - Therefore, Defendants' statements about the company's business operations and prospects lacked a reasonable basis [3]

Apellis Pharmaceuticals, Inc. (APLS) incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share in the year-ago quarter.Total revenues in the third quarter amounted to $196.8 million and missed the Zacks Consensus Estimate of $199 million. In the year-ago quarter, the company had reported revenues of $110.4 million.The top line jumped 78.3% year over year, owing to higher sales of Syfovre (pegcetac ...

Sales of the company's top commercialized product didn't meet expectations.Tuesday's big news with Apellis Pharmaceuticals (APLS -1.70%) wasn't all that favorable to the company. It released its third-quarter results, and the market wasn't all that pleased with the figures.In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By contrast, the S&P 500 (^GSPC 1.23%) index was comfortably in positive territory, with a more than 1% gain at that stage ...

Third Quarter 2024 Financial Results Conference Call November 5, 2024 Apellis Participants | --- | --- | |-------------------------------------------------------------|----------------------------------------------------------| | Co-Founder, President & Chief Executive | C E D R I C F R AN C O I S , M . D . , P h . D . Officer | | AD A M T O W N S E N D Chief Operating Officer | | | C AR O L I N E B AU M A L , M . D . Chief Medical Officer | | | T I M O T H Y S U L L I VAN Chief Financial Officer | | 2 Forw ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Meredith Kaya - Senior Vice President of Investor Relations and Strategic Finance Cedric Francois - Co-Founder and Chief Executive Officer Adam Townsend - Chief Operating Officer Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Salveen Richter - ...

Apellis Pharmaceuticals, Inc. (APLS) reported $196.83 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 78.3%. EPS of -$0.46 for the same period compares to -$1.17 a year ago.The reported revenue represents a surprise of -1.04% over the Zacks Consensus Estimate of $198.89 million. With the consensus EPS estimate being -$0.32, the EPS surprise was -43.75%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -43.75%. A quarter ago, it was expected that this company would post a loss of $0.33 per share when it actually produced a loss of $0.28, delivering a surprise of 15.15%.Over the last four quarters, the compa ...

Financial Performance - Generated $196.8 million in total revenue for Q3 2024, including $152.0 million from SYFOVRE U.S. net product sales and $24.6 million from EMPAVELI U.S. net product sales [1][8] - SYFOVRE U.S. net product revenue grew to $152.0 million in Q3 2024, up from $75.3 million in Q3 2023 [8] - Total revenue increased by 78% year-over-year, from $110.4 million in Q3 2023 to $196.8 million in Q3 2024 [8] - Net loss decreased to $57.4 million in Q3 2024, compared to a net loss of $140.2 million in Q3 2023 [12] SYFOVRE Performance and Market Position - SYFOVRE demand grew by 7% quarter-over-quarter, with U.S. net product revenue of $152.0 million in Q3 2024 [1][3] - More than 88,500 SYFOVRE doses were delivered to physician practices in Q3 2024, including approximately 84,500 commercial vials and 4,000 samples [3] - SYFOVRE remains the market leader in geographic atrophy (GA), with over 420,000 injections administered through September 2024, including clinical trials [3] - A large Medicare Advantage plan will make SYFOVRE the only preferred product on its formulary starting January 1, 2025 [3] R&D and Regulatory Updates - On track to file a supplemental new drug application (sNDA) for pegcetacoplan in C3G and IC-MPGN in early 2025, based on positive 6-month Phase 3 VALIANT results [1][5] - Detailed results from the Phase 3 VALIANT study were presented at Kidney Week 2024, highlighting strong treatment effects in patients with C3G and primary IC-MPGN [5] - Sobi plans to submit a marketing application with the European Medicines Agency in early 2025 and with Japanese Health Authorities in 2025 [6] Cash Position and Financial Outlook - Cash and cash equivalents stood at $396.9 million as of September 30, 2024, up from $351.2 million as of December 31, 2023 [1][13] - The company anticipates that its cash, combined with expected product revenues, will be sufficient to fund operations to positive cash flow [1][13] EMPAVELI Performance - EMPAVELI generated $24.6 million in U.S. net product revenue in Q3 2024, with a high patient compliance rate of 97% [4] - EMPAVELI is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the U.S., European Union, and other countries globally [16] Pipeline and Future Milestones - Enrollment completed in the Phase 2 study evaluating systemic pegcetacoplan in patients with HSCT-TMA, with topline data expected in mid-2025 [6] - Topline data from the Phase 1 dose escalation study of APL-3007 (small interfering RNA silencing C3) is expected in Q1 2025 [6]